Navigation Links
Chimerix to Present at Two Upcoming Investor Conferences
Date:3/25/2011

DURHAM, N.C., March 25, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences in New York City: the Needham & Company 10th Annual Health Care Conference on April 6, 2011 at 8:40am ET at The New York Palace Hotel, and at the BioCentury/Thomson Reuters 18th Annual Future Leaders in the Biotech Industry Conference on April 15, 2011 at 10:00 am ET at the Millennium Broadway Hotel & Conference Center.

Mr. Moch will give an update on the company's pipeline and technology assets, including CMX001, a broad-spectrum antiviral being developed for the treatment of a wide range of infections caused by double-stranded DNA (dsDNA) viruses.  CMX001 is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment and/or prophylaxis of dsDNA viruses, including cytomegalovirus and adenovirus.  It is also undergoing an open-label study for the treatment of patients with any of 12 dsDNA infections which is designed to provide data for CMX001's fundamental studies.  In addition, CMX001 is being developed as a potential countermeasure in the event of a smallpox release.

About Chimerix and CMX001

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.

The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an open-label study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The open-label study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. UO1-AI057233, in addition to new funding from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs. For more information visit www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
2. Chimerix Joins International Network of Organizations to Cure Malaria
3. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
4. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
5. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
6. Chimerix Initiates Phase 1 Study of CMX157
7. Chimerix to Present at Upcoming Investor Conferences
8. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
9. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
10. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
11. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... (PRWEB) , ... August 29, 2020 , ... ... new Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will ... quality standards and advanced technology. , “This facility will improve the flexibility ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society announced ... Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on ... consortium of academic research centers in the United States and Europe with expertise ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a ... has closed on the purchase of greenfield for a new, expanded manufacturing facility. ... over 21 acres in the initial acquisition, with an option to purchase an ...
(Date:7/31/2020)... ... 2020 , ... R3 Stem Cell International is now offering patients the opportunity ... cells total, patients may choose which extremities they would like treated. , Several studies ... Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with ...
Breaking Biology Technology:
(Date:9/3/2020)... ... 2020 , ... Litmus Health , the research-ready infrastructure ... the company’s security practices has been completed. The assessment deemed Litmus infrastructure to ... reviewed Litmus’ processes and systems, assessing them to see whether they adhere to ...
(Date:8/26/2020)... (PRWEB) , ... August 25, ... ... clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex ... enrolment in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic ...
(Date:8/26/2020)... ... ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, is pleased to ... most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions made the Inc. ... growth of 71 percent. , The Inc. 5000 list represents a unique look ...
Breaking Biology News(10 mins):